A 45-Day Study Says Medical Cannabis Outperforms Every Other Anxiety Intervention. Southwest Patients Have Known This for Years.

States: AZ, NM, NV, OK, CO

On any given Tuesday in Tulsa, tens of thousands of Oklahomans are picking up cannabis from one of the state’s nearly 2,000 licensed dispensaries — many of them there for anxiety. They’re not trend-chasers or stoners chasing a high. They’re patients who, by and large, figured something out before the researchers did.

Now the research is catching up.

A longitudinal study published last week in Nature: Scientific Reports offers what may be the most rigorous real-world evidence yet that medical cannabis isn’t just perceived to help with anxiety — it objectively outperforms other intervention strategies patients might use on the same day. The findings come from a 45-day tracked cohort of 416 patients at Florida Gulf Coast University, but the implications land squarely in the Southwest, where medical cannabis programs have been running long enough to produce exactly the kind of patient populations researchers dream about studying.

What the Study Actually Found

Investigators tracked patients’ daily anxiety levels across 45 consecutive days. On some days, participants consumed state-authorized medical cannabis products. On others, they engaged in meditation, exercise, or other anxiety-management techniques. The researchers measured subjective anxiety levels throughout.

The result wasn’t ambiguous: “Medical cannabis use was the biggest factor in alleviating anxiety” across all 45 days, the authors wrote. What’s notable is that it wasn’t just better than doing nothing — it beat the other active interventions measured. And the route of administration — smoking, vaping, edibles, tinctures — made no statistically significant difference to the anxiety relief.

“Investigating how participants administered their MC revealed no effect of route of administration on anxiety relief,” the study noted, which matters for patients who can’t or don’t want to inhale.

This isn’t the first signal. A 2024 NORML-cited survey found more than 90 percent of registered medical patients said cannabis helped relieve their anxiety. What this new 45-day study adds is longitudinal tracking within the same individuals — a methodological step up from cross-sectional surveys that ask “does this generally work?” Rather than asking patients to look backward, it asked them to log forward.

Why the Southwest Is This Story’s Real Home

The Southwest didn’t wait for studies like this to validate what patients were already doing. Several of these states have been running large, mature medical programs for years — in some cases, longer than any other region in the country.

New Mexico launched its medical cannabis program in 2007, one of the earliest in the nation. Patient enrollment has grown steadily ever since, and anxiety disorders have consistently ranked among the top qualifying conditions. New Mexico’s patient population has had nearly two decades to self-select into a model that works for them.

Arizona has been in the medical game since 2010, adding adult-use in 2020. The state now has more than 430,000 active medical cardholders alongside a booming adult-use market — and anxiety remains one of the most commonly cited reasons for registration. The state’s rural corridors, from Flagstaff to Yuma, have seen dispensary access expand significantly in the past three years, bringing formal medical access to communities that previously relied on informal sources.

Nevada was even earlier, approving medical cannabis in 1998 and launching retail in 2015. The state’s program is older than many cannabis companies that now operate there. Las Vegas’s tourism-heavy dispensary market has long catered to occasional visitors, but Clark County also has a dense core of long-term medical patients — many of them elderly, many of them dealing with chronic pain and anxiety simultaneously.

And then there’s Oklahoma.

Oklahoma’s medical cannabis program, launched in 2018, is now routinely cited as the most accessible per-capita in the United States. The state has issued more than 350,000 patient licenses to a population of roughly 4 million — an enrollment rate that dwarfs most of the country. Anxiety is consistently among the top three qualifying conditions. The Oklahoma Medical Marijuana Authority has tracked this population for six years now, making it one of the richest unanalyzed datasets in American cannabis medicine.

Colorado, the grandfather of recreational legalization (2012, adult-use in 2014), has a patient base that predates its rec program. Medical patients here tend to be older and more medically intentional — using cannabis alongside other treatments with physician oversight. For them, research like this isn’t revelatory. It’s validation of a decade’s worth of lived experience.

The Clinical Gap This Research Is Starting to Close

Here’s the frustrating part, and it’s worth saying plainly: anxiety disorders affect more than 40 million Americans. Standard first-line treatments — SSRIs, SNRIs, benzodiazepines — work for many people. They don’t work for everyone. Benzodiazepines carry dependence risks that make long-term prescribing increasingly fraught. SSRIs can take weeks to produce effects and come with their own side-effect profiles.

Cannabis isn’t a miracle drug. The same studies that show anxiety reduction also note potential for elevated anxiety at high THC doses, and individual response varies significantly. But the fact that a patient-controlled, low-barrier intervention tracks favorably against other anxiety-management approaches in a 45-day longitudinal study is clinically meaningful — especially for physicians still hesitant to recommend it.

In states like New Mexico, Arizona, and Oklahoma, physician recommendations are the gateway to the medical program. The more robust the research literature, the more comfortable physicians become recommending — and the more patients can access the formal medical market rather than the informal one.

This study, published in Nature: Scientific Reports rather than a cannabis-adjacent journal, carries weight that advocates’ survey data never quite could.

What Comes Next

The research authors explicitly noted that future work should help “paint a clearer picture of how initiating and maintaining MC use helps individuals deal with daily anxiety levels.” That’s a call for longitudinal cohort studies, ideally across multiple states and demographics — the exact patient populations that states like Oklahoma and Arizona have quietly been building for years.

Whether federal research barriers will ease enough to allow that kind of multi-state, federally funded work remains an open question. Schedule I classification still complicates institutional research even as Schedule III reclassification works its way through the DEA’s administrative review. Researchers at major universities in Colorado and Arizona have navigated these barriers for years, often relying on state-level funding or private partnerships.

But the evidence is accumulating, study by study, in peer-reviewed journals that can’t be dismissed as advocacy publications. For the hundreds of thousands of medical cannabis patients across the Southwest — the people who enrolled in these programs because they needed something that worked — that accumulation matters less as validation than as permission for their neighbors, their physicians, and eventually their elected officials to catch up.

They already know it works. They’ve been tracking it for 45 days, for six years, for nearly two decades.

The research is finally saying so too.

River Nash covers the Southwest cannabis market for CannabisInquirer.com. Reach out at tips@cannabisinquirer.com.